Trial Profile
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 23 Aug 2019 Status changed from recruiting to suspended.
- 27 Jun 2018 Status changed from not yet recruiting to recruiting.
- 12 Feb 2018 New trial record